ROCKWELL MEDICAL,INC. (NASDAQ:RMTI) Files An 8-K Changes in Registrant’s Certifying Accountant

ROCKWELL MEDICAL,INC. (NASDAQ:RMTI) Files An 8-K Changes in Registrant’s Certifying Accountant
Item 4.01 Changes in Registrant’s Certifying Accountant.

Story continues below

On July26, 2018, the Audit Committee of the Board of Directors of Rockwell Medical,Inc. (the “Company”) engagedMarcum LLP(“Marcum”) as the Company’s new independent registered public accounting firm. The engagement of Marcum comes after the resignation of the Company’s former independent registered public accounting firm, Plante& Moran, PLLC (“Plante”), on June22, 2018.

During the two years ended December31, 2017 and 2016 and the subsequent interim periods through July26, 2018, neither the Company, nor anyone on its behalf, has consulted with Marcum regarding: (i)the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements or the effectiveness of internal control over financial reporting, and neither a written report or oral advice was provided to the Company that Marcum concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue; (ii)any matter that was the subject of a disagreement within the meaning of Item 304(a)(1)(iv)of Regulation S-K or (iii)any reportable event within the meaning of Item 304(a)(1)(v)of Regulation S-K, other than informing Marcum of the material weakness in the Company’s internal control over financial reporting and the inability to rely on management representations identified by Plante as described in the Company’s Current Report on Form8-K filed on June27, 2018.

The Audit Committee discussed the subject matter of the reportable events described in the Company’s Current Report on Form8-K filed on June27, 2018 with Plante. The Company has authorized Plante to respond fully to all inquiries of Marcum concerning all matters related to the periods audited by Plante, including with respect to the subject matter of these reportable events.

Item 8.01 Other Events.

On July30, 2018, the Company issued a press release announcing the engagement of Marcum. Attached hereto as Exhibit99.1 and incorporated herein by reference, is a copy of the press release.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits. The following exhibits are being filed herewith:





Press Release, dated July30, 2018.

EX-99.1 2 a18-17944_1ex99d1.htm EX-99.1 Exhibit 99.1   Rockwell Medical Announces Engagement of Marcum LLP as New Independent Auditor   WIXOM,…
To view the full exhibit click here


Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its lead branded drug, Triferic is indicated for iron maintenance. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Its generic drug, Calcitriol, is indicated for treating secondary hyperparathyroidism in dialysis patients. It manufactures, sells, delivers and distributes hemodialysis concentrates, along with a range of ancillary products.

An ad to help with our costs